You just read:

Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor

News provided by

Compugen Ltd.

Feb 20, 2020, 07:00 ET